Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Introduction It has long been recognized that angiogenesis i
2025-02-24

Introduction It has long been recognized that angiogenesis is critical to the growth, progression, and metastasis of many solid tumor types [1], and thus, drugs targeting the angiogenic pathway have been a topic of clinical investigation in the oncology community for many years. Angiogenesis is reg
-
Another class of AMPK regulator is
2025-02-24

Another class of AMPK regulator is peptidyl-prolyl cis/trans isomerase (PPIase) NIMA-interacting 1 (Pin1), which binds to a number of proteins and regulates oncogenesis and metabolic diseases (Khanal et al., 2013; Zhou and Lu, 2016). Pin1 has been shown to bind to and inhibit AMPK; therefore, at lea
-
br STAR Methods br Author Contributions br Acknowledgments T
2025-02-24

STAR★Methods Author Contributions Acknowledgments This study is funded by National Institutes of Health (NIH) Grants NS028901 and DC004450 (to L.O.T.); N.L. Tartar Trust Fellowship (to H.-W.L.); DC014878 to T.S.B. We thank members of the Trussell lab for helpful discussions, Dr. Stephen Dav
-
br Development of lorlatinib from crizotinib
2025-02-24

Development of lorlatinib from crizotinib (1) to a clinical candidate (6) Xalkori (1, PF-02341066, crizotinib), was the first-in-class ALK inhibitor approved by the Unites States Food and Drug Administration (FDA) in 2011 as a first-line treatment for ALK+- NSCLC patients. This section describes
-
The Cebu Longitudinal Health and Nutrition Survey CLHNS geno
2025-02-24

The Cebu Longitudinal Health and Nutrition Survey (CLHNS) genome-wide association study investigated the genetic loci associated with plasma adiponectin in 1776 unrelated Filipino women. Adiponectin was strongly associated with three genetic positions: the gene CDH13 (rs3865188, P ≤ 7.2 × 10−16), ne
-
Introduction Adenosine monophosphate cAMP is
2025-02-24

Introduction Adenosine 3′,5′-monophosphate (cAMP) is a general-purpose signaling molecule present in most branches of life. Intracellular cAMP levels control diverse cellular functions. In bacteria, cAMP regulates metabolism by activation of the catabolite activator protein (CAP), also known as cAM
-
br Methods br Transparency document br
2025-02-21

Methods Transparency document Introduction Epinephrine (EP) is a critical hormone and catecholamine neurotransmitter in nervous system of mammals.1, 2, 3 It has been known to accelerate and regulate heartbeat, blood pressure, bronchodilation, mydriasis, blood sugar and lipolysis, and can he
-
br Trauma and ACEs screening the past present
2025-02-21

Trauma and ACEs screening: the past, present, and future Traditionally, allopathy’s biomedical model has utilized an etic perspective; the outsiders’ view of the problem. Development of diagnostic screening tools requires an etic approach, which relies heavily on a completely objective perspectiv
-
Conclusion Twenty compounds with dinitrobenzoate
2025-02-21

Conclusion Twenty compounds with 3,5-dinitrobenzoate scaffold were synthesized and evaluated using cell-free and HWB assays for their 5-LOX inhibition activities. Compared to the parent compound, six compounds show significantly increased enzyme inhibition activities. The best compound, 3-tolyl 3,5
-
br Disclaimer br Conflicts of interest br Role
2025-02-21

Disclaimer Conflicts of interest Role of the Sponsor Acknowledgements Funding/support: This project was supported by a grant from the Department of Surgery (R5129), Western University and by the Institute for Clinical Evaluative Sciences (ICES) Western site. ICES is funded by an annual g
-
br Phosphorylation of P c Initial studies In
2025-02-21

Phosphorylation of P450c17 – Initial studies In addition to the molar ratio of POR to P450c17 and the allosteric action of cytochrome b5, a third factor that governs 17,20 lyase activity is the serine/threonine (Ser/Thr) phosphorylation of P450c17 itself. In a search for post-translational factor
-
signal transduction inhibitor While the yeasts and see Gloss
2025-02-21

While the yeasts and (see Glossary) each contain only one Aurora homolog, Ipl1p (increase in ploidy 1) and Ark1 (Aurora-related kinase 1), respectively 5, 6, , and Xenopus laevis contain two Aurora kinases: Aurora A and Aurora B [4]. Mammals have three Aurora kinases, A, B, and C (Figure 1). In an
-
We also show that in both ATM proficient and
2025-02-21

We also show that in both ATM proficient and deficient/mutant IETD-AFC cleavage the activation of ATR signaling is DSB complexity-dependent (Figs. 1, 4A, C and E, 6A and B). Wang et al. have also reported that the effects of ATR and CHK1 on radiosensitivity are independent of the NHEJ repair pathwa
-
Similar to other MADS box proteins MEF factors
2025-02-21

Similar to other MADS box proteins, MEF2 factors associate with a variety of transcriptional cofactors to control specific sets of downstream target genes. Some of the cofactors such as MyoD, GATA4, NFAT, TH receptor, p300, 14.3.3 and ERK5 stimulate MEF2 activity, whereas others, such as HDACs4-5-7-
-
br Results br Discussion Although the value
2025-02-21

Results Discussion Although the value of ID specialists in the USA has already been described in the literature, this study suggests that the same holds true for the Japanese healthcare environment [7], [17], [18], [19]. Valerio et al. reported that antifungal use in DDD decreased from 66.4 pe
15531 records 30/1036 page Previous Next First page 上5页 2627282930 下5页 Last page